Register Login

PERSPECTIVE THERAPEUTICS, INC. (CATX)

SymbolCATX
NamePERSPECTIVE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical/Dental Instruments
Address350 HILLS STREET,SUITE 106, RICHLAND, Washington, 99354, United States
Telephone+1 509 375-5329
Fax—
Email—
Websitehttps://www.perspectivetherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0000728387
Description

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Companys melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.

Additional info from NASDAQ:
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Companys melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.

2026-07-29 16:21

New Form SCHEDULE 13G - Perspective Therapeutics, Inc. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0002012383-26-002804 <b>Size:</b> 11 KB

Read more
2026-07-28 10:30

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Read more
2026-07-20 18:24

New Form SCHEDULE 13G - Perspective Therapeutics, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001104659-26-085110 <b>Size:</b> 15 KB

Read more
2026-07-17 16:22

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Read more
2026-07-08 10:30

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor

Read more
2026-06-30 18:37

New Form SCHEDULE 13G - Perspective Therapeutics, Inc. <b>Filed:</b> 2026-06-30 <b>AccNo:</b> 0001104659-26-079425 <b>Size:</b> 15 KB

Read more
2026-06-03 10:30

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Read more
2026-05-27 20:20

(99% Neutral) PERSPECTIVE THERAPEUTICS, INC. (CATX) Announces Regulatory Update

Read more
2026-05-21 21:51

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Read more
2026-05-18 10:30

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06710756 Lead-212 PSV359 Therapy for Patients With Solid Tumors Phase1 Pancreatic Ductal Adenocarcinoma Recruiting 2025-04-28 2032-05-28 ClinicalTrials.gov
NCT06148636 A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors Early_Phase1 Neuroendocrine Tumors Active_Not_Recruiting 2023-11-10 2027-12-31 ClinicalTrials.gov
NCT05636618 Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR… Phase1 Neuroendocrine Tumors Unresectable Recruiting 2023-09-27 2029-12-26 ClinicalTrials.gov
NCT05655312 MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Niv… Phase1 Recurrent Melanoma (Skin) Recruiting 2023-06-01 2029-12-31 ClinicalTrials.gov
NCT05111509 A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent Early_Phase1 Neuroendocrine Tumor Grade 2 Active_Not_Recruiting 2022-08-22 2026-06-30 ClinicalTrials.gov
NCT04904120 Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy Phase1 Melanoma (Skin) Completed 2021-03-05 2022-09-20 ClinicalTrials.gov
Total clinical trials: 6
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
Nivolumab Other Phase PHASE1 Recurrent Melanoma (Skin) RECRUITING NCT05655312
[212Pb]VMT01 Other Phase PHASE1 Recurrent Melanoma (Skin) RECRUITING NCT05655312
[203Pb]VMT01 Other Phase PHASE1 Recurrent Melanoma (Skin) RECRUITING NCT05655312
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[68Ga]VMT02 Other Phase PHASE1 Melanoma (Skin) COMPLETED NCT04904120
[203Pb]VMT01 Other Phase PHASE1 Melanoma (Skin) COMPLETED NCT04904120
SPECT/CT Other Phase EARLY_PHASE1 Neuroendocrine Tumor Grade 2 ACTIVE_NOT_RECRUITING NCT05111509
[203Pb]VMT-α-NET Other Phase EARLY_PHASE1 Neuroendocrine Tumor Grade 2 ACTIVE_NOT_RECRUITING NCT05111509
[203Pb] VMT-α-NET SPECT/CT Other Phase EARLY_PHASE1 Neuroendocrine Tumors ACTIVE_NOT_RECRUITING NCT06148636
[212Pb] VMT-α-NET Other Phase EARLY_PHASE1 Neuroendocrine Tumors ACTIVE_NOT_RECRUITING NCT06148636
Nivolumab Other Phase PHASE1 Recurrent Melanoma (Skin) RECRUITING NCT05655312
[212Pb]VMT01 Other Phase PHASE1 Recurrent Melanoma (Skin) RECRUITING NCT05655312
[203Pb]VMT01 Other Phase PHASE1 Recurrent Melanoma (Skin) RECRUITING NCT05655312
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[203Pb]Pb-PSV359 Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma RECRUITING NCT06710756
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[212Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
[203Pb]VMT-α-NET Other Phase PHASE1 Neuroendocrine Tumors Unresectable RECRUITING NCT05636618
Total products: 92